Search Results
28 results found-
OFR 1 Chair and CEO message 2 8 Environment 46 2 Our Company 8 9 Social 53 3 CSL's Performance and Strategy 20 OFR 10 CSL's Governance 60 4 CSL's Material Risks 26 11 Share Information 70 5 CSL's Future Prospects 28 12 Key Performance Data Summary 73 6 Powered by Innovation 32 13 Medical Glossary 74 7 CSL's People 40 OFR 14 Financial Performance 75
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
Consolidated CSL Behring CSL Seqirus CSL Vifor Entity US$m 2024 2023 2024 2023 2024 2023 2024 2023 Sales and service revenue 10,334 8,968 1,896 1,851 2,029 1,957 14,259 12,776 Influenza pandemic facility reservation fees — — 172 156 — — 172 156 Royalty and license revenue 235 215 — — 24 27 259 242 Other income 39 107 60 24 11 5 110 136 Total segment revenue 10,608 9,290 2,128 2,031 2,064 1,989 14,800 13,310 Segment gross profit 5,275 4,561 1,318 1,259 1,413 1,411 8,006 7,231 Segment gross profit % 49.7% 49.1% 61.9% 62.0% 68.5% 70.9 % 54.1% 54.3% Selling and marketing expenses (903) (804) (196) (187) (457) (490) (1,556) (1,481) Segment operating result 4,372 3,757 1,122 1,072 956 921 6,450 5,750 Segment operating result % 41.2% 40.4% 52.7% 52.8% 46.3% 46.3 % 43.6% 43.2% Research and development expenses (1,428) (1,266) General and administrative expenses (825) (827) Underlying EBIT 4,197 3,657 Finance costs (476) (444) Finance income 39 38 Profit before tax 3,760 3,251 Income tax expense (722) (504) NPATA 3,038 2,747 - Attributable to equity holders of CSL 2,907 2,610 - Attributable to non-controlling interests 131 137 Underlying EBIT 4,197 3,657 Unwind of CSL Vifor inventory fair value uplift (30) (169) CSL Vifor acquisition and integration costs (54) (184) Amortisation of other intangibles (excluding IP)1 5 3 16 14 7 9 109 106 Depreciation1 337 273 60 60 25 24 528 490 EBITDA2 4,714 4,033 1,198 1,146 988 954 4,750 3,900
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2024.pdf -
Limit the daily dose of simvastatin (20 mg) and rosuvastatin (5 mg).
https://newsroom.csl.com/2024-03-28-Vafseo-R-approved-by-the-U-S-FDA-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-dialysis-dependent-adult-patients -
Biotech leader CSL has manufacturing centers, sales offices, and locations to serve patients and public health around the globe.
https://www.csl.com/we-are-csl/worldwide-locations -
This was added as a gateway condition of the LTI target to ensure the ROIC is delivering an appropriate return each financial year as well as over the seven year rolling 0% 20% 40% 60% 80% 100% average period and aligns with shareholder outcomes.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
For our executive KMP in 2019, the Board has approved an average 4% increase in Fixed Reward, no increase in STI and an average 30% increase 0% 20% 40% 60% 80% 100% in LTI targets to recognise that our executive KMP LTI component is significantly below global market comparators.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
68 CSL Limited Annual Report 2017 200 60% 35% 35% 35% 160 43% 43% 43% 43% 43% 60% 120 43% 43% 43% 43% 43% 80 35% 35% 35% 40 120% 70% 85% 70% 85% 85% 70% 85% 85% 0 L Reed L Reed G Boss G Boss G Naylor G Naylor R Repella R Repella D Lamont D Lamont P Perreault P Perreault V Romberg V Romberg K Etchberger K Etchberger A Cuthbertson A Cuthbertson
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2017-full.pdf -
VFMCRPE 2023 Federación Nacional ALCER ESPAÑA Patrocinio 36ª ED.
https://www.csl.com/-/media/shared/documents/vifor-disclosures/tov/20240621transparencia-organizacin-de-pacientes-2023final-v2-1.pdf -
MIGUEL SERVET- C. DE IRUNLARREA, 3 - PAMPLONA/IRUÑA Spain G31187420 8.000,00 8.000,00 NAVARRABIOM 31008-PAM ED
https://www.csl.com/-/media/shared/documents/vifor-disclosures/tov/spain-efpia_sp08july2024-updated-final.pdf -
Ready for a challenge? CSL's Summer Internship Program offers roles in Engineering, Manufacturing, Research & Development, Business Operations, and more
https://www.csl.com/careers/early-careers-at-csl/internships/internships-in-the-us